Recent Advances in Cystic Fibrosis

Clinics in Chest Medicine

Volumn 33, Issue 2, 2012, Pages 307-328

  Lobo, Jason ^a   Rojas Balcazar, Juan M ^a   Noone, Peadar G ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Bronchiectasis; CFTR; Cystic fibrosis; Gene modifiers; Mucociliary clearance; Pseudomonas aeruginosa

Indexed keywords

ACETYLCYSTEINE; ALPHA 1 ANTITRYPSIN; AMIKACIN; AMINOGLYCOSIDE; ATALUREN; AZITHROMYCIN; AZTREONAM; CIPROFLOXACIN; COLISTIN; DENUFOSOL; GLUCOCORTICOID; GLUTATHIONE; IBUPROFEN; IVACAFTOR; LUMACAFTOR; MANNITOL; PLACEBO; PURINERGIC P2Y RECEPTOR AGONIST; PURINERGIC P2Y2 RECEPTOR AGONIST; SILDENAFIL; SODIUM CHLORIDE; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; VARDENAFIL;

ATYPICAL MYCOBACTERIUM; BACTERIUM DETECTION; BIOFILM; BURKHOLDERIA CEPACIA; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; FUNGUS; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC RISK; GENOTYPE PHENOTYPE CORRELATION; HAEMOPHILUS INFLUENZAE; HUMAN; ION TRANSPORT; LUNG CLEARANCE; LUNG FLUID; MOLECULAR THERAPY; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; REGULATOR GENE; REVIEW; STAPHYLOCOCCUS AUREUS; SURVIVAL RATE; TOTAL QUALITY MANAGEMENT; UNFOLDED PROTEIN RESPONSE; VIRUS;

CYSTIC FIBROSIS; DELIVERY OF HEALTH CARE; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY IMPROVEMENT;

EID: 84861541742     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2012.02.006     Document Type: Review

References (126)

1. Boucher R.C., Knowles M.R., Yankaskas J.R. Cystic fibrosis. Murray and Nadel's textbook of respiratory medicine 2010, 985-1022. Elsevier, Philadelphia. 5th edition. R.J. Mason, T. Martin, T. King (Eds.).
2. Cohen-Cymberknoh M., Shoseyov D., Kerem E. Managing cystic fibrosis strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med 2011, 183:1463-1471.
3. Cystic Fibrosis Foundation Patient Registry. 2010 Annual Report to the Center Directors. Cystic fibrosis foundation annual data report 2010. 2011. p. 2-3. Available at: Accessed February 22, 2012. http://www.cff.org.
4. Cutting G.R. Modifier genes in mendelian disorders: the example of cystic fibrosis. Ann N Y Acad Sci 2010, 1214:57-69.
5. Rogan M.P., Stoltz D.A., Hornick D.B. Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment. Chest 2011, 139:1480-1490.
6. Noone P.G., Pue C.A., Zhou Z., et al. Lung disease associated with the IVS8 5T allele of the CFTR gene. Am J Respir Crit Care Med 2000, 162:1919-1924.
7. Li W., Sun L., Corey M., et al. Understanding the population structure of North American patients with cystic fibrosis. Clin Genet 2011, 79:136-146.
8. Vanscoy L.L., Blackman S.M., Collaco J.M., et al. Heritability of lung disease severity in cystic fibrosis. Am J Respir Crit Care Med 2007, 175:1036-1043.
9. Wright F.A., Strug L.J., Doshi V.K., et al. Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat Genet 2011, 43:539-546.
10. Blohmke C.J., Park J., Hirschfeld A.F., et al. TLR5 as an anti-inflammatory target and modifier gene in cystic fibrosis. J Immunol 2010, 185:7731-7738.
11. Bartlett J.R., Friedman K.J., Ling S.C., et al. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009, 302:1076-1083.
12. Dorfman R., Taylor C., Lin F., et al. Modulatory effect of the SLC9A3 gene on susceptibility to infections and pulmonary function in children with cystic fibrosis. Pediatr Pulmonol 2011, 46:385-392.
13. Blackman S.M., Hsu S., Ritter S.E., et al. A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis. Diabetologia 2009, 52:1858-1865.
14. Pittman J.E., Calloway E.H., Kiser M., et al. Age of Pseudomonas aeruginosa acquisition and subsequent severity of cystic fibrosis lung disease. Pediatr Pulmonol 2011, 46:497-504.
15. Dasenbrook E.C., Checkley W., Merlo C.A., et al. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 2010, 303:2386-2392.
16. Dasenbrook E.C., Merlo C.A., Diener-West M., et al. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med 2008, 178:814-821.
17. Jones A.M., Dodd M.E., Govan J.R., et al. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax 2004, 59:948-951.
18. Razvi S., Quittell L., Sewall A., et al. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest 2009, 136:1554-1560.
19. Kunst H., Wickremasinghe M., Wells A., et al. Nontuberculous mycobacterial disease and Aspergillus-related lung disease in bronchiectasis. Eur Respir J 2006, 28:352-357.
20. Esther C.R., Esserman D.A., Gilligan P., et al. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010, 9:117-123.
21. Wolfenden L.L., Schechter M.S. Genetic and non-genetic determinants of outcomes in cystic fibrosis. Paediatr Respir Rev 2009, 10:32-36.
22. Schechter M.S. Non-genetic influences on cystic fibrosis lung disease: the role of sociodemographic characteristics, environmental exposures, and healthcare interventions. Semin Respir Crit Care Med 2003, 24:639-652.
23. Tippets B.M., Shoff S.M., Lin F., et al. CF newborn screening in Wisconsin: comparison of pulmonary outcomes during the first six years of life between children diagnosed during the randomized clinical trial (1985-1994) and the Routine Program (1994-2003). Abstract at the NACF meeting, 2009. Pediatr Pulmonol 2009, 351.
24. Sanders D., Lai H.J., Rock M., et al. Infants with CF diagnosed in IRT/DNA states are treated earlier than those diagnosed in IRT/IRT states. Abstract at the NACF meeting, 2009. Pediatr Pulmonol 2010, 389.
25. Quittner A.L., Schechter M.S., Rasouliyan L., et al. Impact of socioeconomic status, race, and ethnicity on quality of life in patients with cystic fibrosis in the United States. Chest 2010, 137:642-650.
26. Knowles M.R., Durie P.R. What is cystic fibrosis?. N Engl J Med 2002, 347:439-442.
27. Smith J.J., Travis S.M., Welsh M.J. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface liquid. Cell 1996, 85:229-236.
28. Matsui H., Grubb B.R., Tarran R., et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998, 95:1-20.
29. Boucher R.C. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med 2007, 58:157-170.
30. Donaldson S.H., Boucher R.C. Sodium channels and cystic fibrosis. Chest 2007, 132:1631-1636.
31. Clunes M.T., Boucher R.C. Cystic fibrosis: the mechanisms of pathogenesis of an inherited lung disorder. Drug Discov Today Dis Mech 2007, 4:63-72.
32. Ferrera L., Caputo A., Galietta L.J. TMEM16A protein: a new identity for Ca(2+)-dependent Cl(-) channels. Physiology 2010, 25:357-363.
33. Voynow J.A., Rubin B.K. Mucins, mucus, and sputum. Chest 2009, 135:505-512.
34. Chen J.H., Stoltz D.A., Karp P.H., et al. Loss of anion transport without increased sodium absorption characterizes newborn porcine cystic fibrosis airway epithelia. Cell 2010, 143:911-923.
35. Ribeiro C.M., Boucher R.C. Role of endoplasmic reticulum stress in cystic fibrosis-related airway inflammatory responses. Proc Am Thorac Soc 2010, 7:387-394.
36. Wilke M., Buijs-Offerman R.M., Aarbiou J., et al. Mouse models of cystic fibrosis: phenotypic analysis and research applications. J Cyst Fibros 2011, 10:S152-S171.
37. Keiser N.W., Engelhardt J.F. New animal models of cystic fibrosis: what are they teaching us?. Curr Opin Pulm Med 2011, 17:478-483.
38. Zhou Z., Duerr J., Johannesson B., et al. The beta ENaC-overexpressing mouse as a model of cystic fibrosis lung disease. J Cyst Fibros 2011, 10:S172-S182.
39. Rogers C.S., Stoltz D.A., Meyerholz D.K., et al. Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science 2008, 321:1837-1841.
40. Stoltz D.A., Meyerholz D.K., Pezzulo A.A., et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med 2010, 2:29-31.
41. Meyerholz D.K., Stoltz D.A., Namati E., et al. Loss of cystic fibrosis transmembrane conductance regulator function produces abnormalities in tracheal development in neonatal pigs and young children. Am J Respir Crit Care Med 2010, 182:1251-1261.
42. Sun X.S., Sui H.S., Fisher J.T., et al. Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis. J Clin Invest 2010, 120:3149-3160.
43. Kerem E., Bistritzer T., Hanukoglu A., et al. Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in pseudohypoaldosteronism. N Engl J Med 1999, 341:156-162.
44. Pillarisetti N., Williamson E., Linnane B., et al. Infection, inflammation, and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med 2011, 184:75-81.
45. Wojewodka G., De Sanctis J.B., Radzioch D. Ceramide in cystic fibrosis: a potential new target for therapeutic intervention. J Lipids 2011, 2011:1-12.
46. Debray D., Kelly D., Houwen R., et al. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros 2011, 10:S29-S36.
47. Freudenberg F., Leonard M.R., Liu S.A., et al. Pathophysiological preconditions promoting mixed "black" pigment plus cholesterol gallstones in a Delta F508 mouse model of cystic fibrosis. Am J Physiol Gastrointest Liver Physiol 2010, 299:G205-G214.
48. Meyerholz D.K., Stoltz D.A., Pezzulo A.A., et al. Pathology of gastrointestinal organs in a porcine model of cystic fibrosis. Am J Pathol 2010, 176:1377-1389.
49. Rowland M., Gallagher C.G., O'Laoide R., et al. Outcome in cystic fibrosis liver disease. Am J Gastroenterol 2011, 106:104-109.
50. Chryssostalis A., Hubert D., Coste J., et al. Liver disease in adult patients with cystic fibrosis: a frequent and independent prognostic factor associated with death or lung transplantation. J Hepatol 2011, 55(6):1377-1382.
51. Wouthuyzen-Bakker M., Bodewes F.A., Verkade H.J. Persistent fat malabsorption in cystic fibrosis; lessons from patients and mice. J Cyst Fibros 2011, 10:150-158.
52. Cohn J.A., Noone P.G., Jowell P.S. Idiopathic pancreatitis related to CFTR: complex inheritance and identification of a modifier gene. J Investig Med 2002, 50:247S-255S.
53. Ooi C.Y., Dorfman R., Cipolli M., et al. Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. Gastroenterology 2011, 140:153-161.
54. Chamnan P., Shine B.S., Haworth C.S., et al. Diabetes as a determinant of mortality in cystic fibrosis. Diabetes Care 2010, 33:311-316.
55. van der Doef H.P., Kokke F.T., Beek F.J., et al. Constipation in pediatric cystic fibrosis patients: an underestimated medical condition. J Cyst Fibros 2010, 9:59-63.
56. Colombo C., Ellemunter H., Houwen R., et al. Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. J Cyst Fibros 2011, 10:S24-S28.
57. Werlin S.L., Benuri-Silbiger I., Kerem E., et al. Evidence of intestinal inflammation in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2010, 51:304-308.
58. Millar F.A., Simmonds N.J., Hodson M.E. Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985-2005. J Cyst Fibros 2009, 8:386-391.
59. Rosenfeld M., Gibson R.L., McNamara S., et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 2001, 32:356-366.
60. Rosenfeld M., Emerson J., Accurso F., et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999, 28:321-328.
61. Gibson R.L., Burns J.L., Ramsey B.W. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003, 168:918-951.
62. Bittar F., Richet H., Dubus J.C., et al. Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. Plos One 2008, 3:e2908.
63. Sibley C.D., Parkins M.D., Rabin H.R., et al. A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc Natl Acad Sci U S A 2008, 105:15070-15075.
64. Rogers G.B., Hoffman L.R., Whiteley M., et al. Revealing the dynamics of polymicrobial infections: implications for antibiotic therapy. Trends Microbiol 2010, 18:357-364.
65. Harris J.K., De Groote M.A., Sagel S.D., et al. Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc Natl Acad Sci U S A 2007, 104:20529-20533.
66. Stuart B., Lin J.H., Mogayzel P.J. Early eradication of pseudomonas aeruginosa in patients with cystic fibrosis. Paediatr Respir Rev 2010, 11:177-184.
67. Juhas M., Eberl L., Tummler B. Quorum sensing: the power of cooperation in the world of pseudomonas. Environ Microbiol 2005, 7:459-471.
68. Cigana C., Curcuru L., Leone M.R., et al. Pseudomonas aeruginosa exploits lipid A and muropeptides modification as a strategy to lower innate immunity during cystic fibrosis lung infection. Plos One 2009, 4:e8439.
69. Foweraker J.E., Laughton C.R., Brown D.F., et al. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J Antimicrob Chemother 2005, 55:921-927.
70. Smith A.L., Fiel S.B., Mayer-Hamblett N., et al. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003, 123:1495-1502.
71. Govan J.R., Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996, 60:539-574.
72. Taccetti G., Campana S., Festini F., et al. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005, 26:458-461.
73. Govan J.R., Brown A.R., Jones A.M. Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection. Future Microbiol 2007, 2:153-164.
74. Liou T.G., Adler F.R., Fitzsimmons S.C., et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001, 153:345-352.
75. Aris R.M., Routh J.C., Lipuma J.J., et al. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type. Am J Respir Crit Care Med 2001, 164:2102-2106.
76. Hadjiliadis D. Special considerations for patients with cystic fibrosis undergoing lung transplantation. Chest 2007, 131:1224-1231.
77. Murray S., Charbeneau J., Marshall B.C., et al. Impact of Burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med 2008, 178:363-371.
78. Kahl B.C., Duebbers A., Lubritz G., et al. Population dynamics of persistent Staphylococcus aureus isolated from the airways of cystic fibrosis patients during a 6-year prospective study. J Clin Microbiol 2003, 41:4424-4427.
79. Vergison A., Denis O., Deplano A., et al. National survey of molecular epidemiology of Staphylococcus aureus colonization in Belgian cystic fibrosis patients. J Antimicrob Chemother 2007, 59:893-899.
80. Navarro J., Rainisio M., Harms H.K., et al. Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF. Eur Respir J 2001, 18:298-305.
81. Huang N.N., Schidlow D.V., Szatrowski T.H., et al. Clinical-features, survival rate, and prognostic factors in young-adults with cystic-fibrosis. Am J Med 1987, 82:871-879.
82. Roman F., Canton R., Perez-Vazquez M., et al. Dynamics of long-term colonization of respiratory tract by Haemophilus influenzae in cystic fibrosis patients shows a marked increase in hypermutable strains. J Clin Microbiol 2004, 42:1450-1459.
83. Rayner R.J., Hiller E.J., Ispahani P., et al. Haemophilus infection in cystic-fibrosis. Arch Dis Child 1990, 65:255-258.
84. De Baets F., Schelstraete P., Van Daele S., et al. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. J Cyst Fibros 2007, 6:75-78.
85. Wellinghausen N., Kothe J., Wirths B., et al. Superiority of molecular techniques for identification of gram-negative, oxidase-positive rods, including morphologically nontypical Pseudomonas aeruginosa, from patients with cystic fibrosis. J Clin Microbiol 2005, 43:4070-4075.
86. Rogers G.B., Carroll M.P., Stressmann F.A., et al. Cystic fibrosis lung infections: from ecological insights to clinical benefit. Abstract at the NACF meeting, 2009. Pediatr Pulmonol 2010, 189-191.
87. Tunney M., Moriarty F., Field T., et al. Detection of anaerobic bacteria in sputum from cystic fibrosis patients with an acute pulmonary exacerbation. Abstract at the NACF meeting, 2009. Pediatr Pulmonol 2007, 311-312.
88. Ulrich M., Beer I., Braitmaier P., et al. Relative contribution of Prevotella intermedia and Pseudomonas aeruginosa to lung pathology in airways of patients with cystic fibrosis. Thorax 2010, 65:978-984.
89. Tunney M.M., Klem E.R., Fodor A.A., et al. Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis. Thorax 2011, 66:579-584.
90. Worlitzsch D., Rintelen C., Bohm K., et al. Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients. Clin Microbiol Infect 2009, 15:454-460.
91. Olivier K.N., Weber D.J., Wallace R.J., et al. Nontuberculous mycobacteria: I. Multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003, 167:828-834.
92. Rodman D.M., Polis J.M., Heltshe S.L., et al. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am J Respir Crit Care Med 2005, 171:621-626.
93. Torrens J.K., Dawkins P., Conway S.P., et al. Non-tuberculous mycobacteria in cystic fibrosis. Thorax 1998, 53:182-185.
94. Lee B., Schjerling C.K., Kirkby N., et al. Mucoid Pseudomonas aeruginosa isolates maintain the biofilm formation capacity and the gene expression profiles during the chronic lung infection of CF patients. APMIS 2011, 119:263-274.
95. Stevens D.A., Moss R.B., Kurup V.P., et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis: state of the art: Cystic Fibrosis Foundation Consensus Conference (vol 37, pg S225, 2003). Clin Infect Dis 2004, 38:158.
96. Kistler A., Avila P.C., Rouskin S., et al. Pan-viral screening of respiratory tract infections in adults with and without asthma reveals unexpected human coronavirus and human rhinovirus diversity. J Infect Dis 2007, 196:817-825.
97. Cystic Fibrosis Foundation Patient Registry. 2009 Annual Report to the Center Directors. Cystic fibrosis foundation annual data report 2009. 2010. p. 2-3. Available at: http://www.cff.org.
98. Griesenbach U., Alton E.W. Current status and future directions of gene and cell therapy for cystic fibrosis. BioDrugs 2011, 25:77-88.
99. Noone P.G., Hohneker K.W., Zhou Z., et al. Safety and biological efficacy of a lipid-CFTR complex for gene transfer in the nasal epithelium of adult patients with cystic fibrosis. Mol Ther 2000, 1:105-114.
100. Kerem E., Hirawat S., Armoni S., et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008, 372:719-727.
101. Clancy J.P., Rowe S.M., Durie P.R., et al. Comparison of NPD parameters in a phase IIA study to optimize detection of CFTR modulator bioactivity in clinical trials. Abstract at the NACF meeting, 2009. Pediatr Pulmonol 2010, 301.
102. Ramsey B.W., Davies J., McElvaney N.G., et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011, 365(18):1663-1672.
103. Donaldson S.H., Bennett W.D., Zeman K.L., et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006, 354:241-250.
104. Daviskas E., Anderson S.D., Jaques A., et al. Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis. Chest 2010, 137:861-868.
105. Accurso F.J., Moss R.B., Wilmott R.W., et al. Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. Am J Respir Crit Care Med 2011, 183:627-634.
106. Batacchi S., Zagli G., Peris A., et al. Totally implantable vascular access devices in adult patients for cystic fibrosis management. Am J Respir Crit Care Med 2011, 183:133-134.
107. Retsch-Bogart G.Z., Quittner A.L., Gibson R.L., et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009, 135:1223-1232.
108. Ratjen F., Munck A., Kho P., et al. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010, 65:286-291.
109. Giuliano C.A., Dehoorne-Smith M.L., Kale-Pradhan P.B. Pancreatic enzyme products: digesting the changes. Ann Pharmacother 2011, 45:658-666.
110. Mohan K., Israel K.L., Miller H., et al. Long-term effect of insulin treatment in cystic fibrosis-related diabetes. Respiration 2008, 76:181-186.
111. Koch C., Cuppens H., Rainisio M., et al. European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations. Pediatr Pulmonol 2001, 31:1-12.
112. Goldbeck L., Zerrer S., Schmitz T.G. Monitoring quality of life in outpatients with cystic fibrosis: feasibility and longitudinal results. J Cyst Fibros 2007, 6:171-178.
113. Goss C.H., Burns J.L. Exacerbations in cystic fibrosis center dot 1: epidemiology and pathogenesis. Thorax 2007, 62:360-367.
114. de Boer K., Vandemheen K.L., Tullis E., et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax 2011, 66:680-685.
115. Pedreira C.C., Robert R.G., Dalton V., et al. Association of body composition and lung function in children with cystic fibrosis. Pediatr Pulmonol 2005, 39:276-280.
116. Farrell P.M., Kosorok M.R., Laxova A., et al. Nutritional benefits of neonatal screening for cystic fibrosis. N Engl J Med 1997, 337:963-969.
117. Tluczek A., Becker T., Laxova A., et al. Relationships among health-related quality of life, pulmonary health, and newborn screening for cystic fibrosis. Chest 2011, 140:170-177.
118. Sood N., Paradowski L.J., Yankaskas J.R. Outcomes of intensive care unit care in adults with cystic fibrosis. Am J Respir Crit Care Med 2001, 163:335-338.
119. Slieker M.G., van Gestel J.P., Heijerman H.G., et al. Outcome of assisted ventilation for acute respiratory failure in cystic fibrosis. Intensive Care Med 2006, 32:754-758.
120. Hayes D., Mansour H. Improved outcomes of patients with end-stage cystic fibrosis requiring invasive mechanical ventilation for acute respiratory failure. Lung 2011, 189:409-415.
121. Lau E.M., Barnes D.J., Moriarty C., et al. Pregnancy outcomes in the current era of cystic fibrosis care: a 15-year experience. Aust N Z J Obstet Gynaecol 2011, 51:220-224.
122. Quittner A.L., Barker D.H., Snell C., et al. Prevalence and impact of depression in cystic fibrosis. Curr Opin Pulm Med 2008, 14:582-588.
123. Kraynack N.C., McBride J.T. Improving care at cystic fibrosis centers through quality improvement. Semin Respir Crit Care Med 2009, 30:547-558.
124. Marshall B.C., Penland C.M., Hazle L., et al. Cystic Fibrosis Foundation: achieving the mission. Respir Care 2009, 54:788-795.
125. Quinton H.B., O'Connor G.T. Current issues in quality improvement in cystic fibrosis. Clin Chest Med 2007, 28:459-472.
126. Quon B.S., Goss C.H. A story of success: continuous quality improvement in cystic fibrosis care in the USA. Thorax 2011, 66(12):1106-1108.